NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW.

Today, 7 October 2024, the exercise period for Toleranzia AB's (“Toleranzia” or the “Company”) warrants of series TO4 (“TO4”) issued in connection with the rights issue of units resolved in August 2023 begins. One (1) TO4 entitles the holder to subscribe for one (1) new share in the Company. The subscription price per share subscribed for through the utilisation of TO4 is set at SEK 0.50 per share. The exercise period for TO4 runs until 21 October 2024. Upon full exercise of all TO4, Toleranzia will receive approximately SEK 43.4 million before issue related costs. As communicated by way of a press release on 28 August 2024, the Company has received subscription commitments corresponding to approximately 71.14 percent of the issue proceeds that the Company can receive through the utilisation of TO4.
 
Summary of terms and conditions for TO4:

• Terms and conditions: One (1) TO4 entitles the holder to subscribe for one (1) new share in the Company
• Subscription price: SEK 0.50 per share
• Exercise period: From 7 October 2024 until 21 October 2024
• Last day of trading in TO4: 17 October 2024

Please note that TO4 that are not actively exercised for subscription of shares by 21 October 2024, or sold by 17 October 2024, will expire worthless. Active subscription of shares or disposal of warrants is required for the warrants not to lapse.
 
How TO4 is utilised:
 
Trustee registered TO4 (custody account)
Holders whose holdings of TO4 are registered in the name of a nominee must notify the exercise of TO4 by contacting their nominee and follow the nominee's instructions regarding subscription and payment. Note that nominees may have an earlier response date for subscription of shares through the use of TO4. Holders who have their holdings of TO4 nominee-registered are therefore encouraged to contact their nominee at an early stage.
 
Directly registered TO4 (VP-account)
Holders who have their TO4 directly registered must notify the utilisation of TO4 by completing and submitting the application form for utilisation, so that the application form is received by the issuer agent Nordic Issuing AB no later than 21 October 2024. The application form is available on the Company's and the issuer agent's respective websites.
 
Full terms and conditions for TO4 are available on the Company's website, www.toleranzia.com.
 
Number of shares, share capital and dilution
Upon full utilisation of all TO4, the share capital will increase by SEK 10,844,455.5 to SEK 35,478,314.875 through the issue of 86,755,644 shares, meaning that the total number of outstanding shares in the Company will increase from 197,070,875 to 283,826,519. The dilution upon full utilisation of TO4 amounts to approximately 30.56 per cent.
 
For further information, please contact
Charlotte Fribert - CEO, Toleranzia AB
Tel: +46 763 19 98 98
E-mail: charlotte.fribert@toleranzia.com   

About Toleranzia AB (publ)
Toleranzia AB (publ) develops medicines that harness the power of the immune system to treat rare autoimmune diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, just reduce symptoms. They have the potential to be the first long-acting or curative treatments that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the company's Certified Adviser.